These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 15754125

  • 1. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.
    Achiron A, Barak Y, Gail M, Mandel M, Pee D, Ayyagari R, Rotstein Z.
    Breast Cancer Res Treat; 2005 Feb; 89(3):265-70. PubMed ID: 15754125
    [Abstract] [Full Text] [Related]

  • 2. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
    Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, Wiertlevski S, Defer G, Gout O, Berthier F, Danzon A.
    Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W, Erasmus LP, Feneberg W, Straube A.
    Neurology; 2006 Jan 24; 66(2):275-7. PubMed ID: 16434675
    [Abstract] [Full Text] [Related]

  • 5. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
    Ouallet JC.
    Rev Neurol (Paris); 2010 Jan 24; 166(1):21-31. PubMed ID: 19596382
    [Abstract] [Full Text] [Related]

  • 6. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
    Sarchielli P, Zaffaroni M, Floridi A, Greco L, Candeliere A, Mattioni A, Tenaglia S, Di Filippo M, Calabresi P.
    Mult Scler; 2007 Apr 24; 13(3):313-31. PubMed ID: 17439900
    [Abstract] [Full Text] [Related]

  • 7. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J, Cristiano E.
    Medicina (B Aires); 2001 Apr 24; 61(4):470-80. PubMed ID: 11563177
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B, Beelen R, Hoek G, Schouten L, Bausch-Goldbohm S, Fischer P, Armstrong B, Hughes E, Jerrett M, van den Brandt P.
    Res Rep Health Eff Inst; 2009 Mar 24; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S, Nippert I, Scherer P, Haas J, Pöhlau D, Kugler J.
    Curr Med Res Opin; 2007 Jun 24; 23(6):1209-15. PubMed ID: 17559722
    [Abstract] [Full Text] [Related]

  • 12. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis.
    Lage MJ, Castelli-Haley J, Oleen-Burkey MA.
    Work; 2006 Jun 24; 27(2):143-51. PubMed ID: 16971761
    [Abstract] [Full Text] [Related]

  • 13. [Recent therapeutic strategy for multiple sclerosis].
    Itoyama Y.
    Rinsho Shinkeigaku; 2001 Dec 24; 41(12):1214-7. PubMed ID: 12235841
    [Abstract] [Full Text] [Related]

  • 14. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C, Vukusic S.
    Clin Neurol Neurosurg; 2004 Jun 24; 106(3):263-9. PubMed ID: 15177781
    [Abstract] [Full Text] [Related]

  • 15. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    Neuhaus O, Stüve O, Archelos JJ, Hartung HP.
    J Neurol Sci; 2005 Jun 15; 233(1-2):173-7. PubMed ID: 15949504
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC.
    Value Health; 2004 Jun 15; 7(5):554-68. PubMed ID: 15367251
    [Abstract] [Full Text] [Related]

  • 19. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 15; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 20. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence.
    Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE.
    J Natl Cancer Inst; 2007 Apr 18; 99(8):608-15. PubMed ID: 17440162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.